Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis Journal of Neuro-Oncology, 05/25/2012

Horak P et al. – The authors conclude that single–agent imatinib mesylate might be a well–tolerated therapeutic option with high achievement of disease stabilization for preselected patients with recurrent meningiomas. Because of the small cohort, non–randomized design, and highly diverse patient population, they propose future prospective studies to validate the results.

Read this article on Journal of Neuro-Oncology

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Nursing Jobs
@MDLinx Career Center
View the full listing of nursing jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?